Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Redbook US Same-Store Sales Rise in Week Ended Aug. 29

Redbook US Same-Store Sales Rise in Week Ended Aug. 29

MT newswireMT newswire2026/09/01 12:55
08:55 AM EDT, 09/01/2026 (MT Newswires) -- Redbook US same-store sales rose by 9.6% from a year earlier in the week ended Aug. 29 after a 9.1% year-over-year increase in the previous week. Redbook noted that most companies reported strong back-to-school demand for children's and juniors' apparel and footwear. "Shoppers are focusing on value and are shopping more at warehouse clubs and discount stores," Redbook said. Through the fourth selling week for August, sales were up 8.7% compared with August 2025, slightly below the target for an 8.8% gain, Redbook said. The early target for sales in September is 8.6% increase from the previous year, Redbook said. Next week's report will be released on Wednesday, Sept. 9 due to the Labor Day holiday on Monday.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Intel Confirms Advancement of Musk's "Terafab" Chip Plan Amid Stock Price Pressure

Intel CEO Pat Gelsinger stated that the company will continue to participate in Elon Musk's Terafab project. Previously, Musk revealed ongoing discussions with TSMC about potential collaboration, which raised market concerns over Intel's position in the project. As a result, Intel's stock price once dropped by 3.9%.

华尔街见闻•2026/10/07 10:09

BUZZ-Caribou shares plunge as company explores sale and cancels cancer project

October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)

路透社•2026/10/07 09:39